TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33256419

Group type: EXPERIMENTAL
Intervention: Pylera® (quadruple therapy)
Number of subjects: 108

Group type: COMPARATOR
Intervention: AST-guided triple therapy
Number of subjects: 108

Group type: COMPARATOR
Intervention: Both groups (Pylera® and AST-guided triple therapy)
Number of subjects: 108
Study: 36127718

Group type: EXPERIMENTAL
Intervention: SH2018-10 miniscrews (length 10 mm, ø 1.8-2.0 mm)
Number of subjects: 92

Group type: COMPARATOR
Intervention: SH1514-08 miniscrews (length 8 mm, ø 1.4-1.5 mm)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: SH2018-10 miniscrews
Number of subjects: 92

Group type: COMPARATOR
Intervention: SH1514-08 miniscrews
Number of subjects: 92
Study: 33709870

Group type: EXPERIMENTAL
Intervention: Gain-framed message fit with promotion focus
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gain-framed message nonfit with prevention focus
Number of subjects: 0
Study: 32719981

Group type: EXPERIMENTAL
Intervention: Eldecalcitol (ELD) 0.75 μg once-a-day for 24 weeks
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Alendronate (ALN) 35 mg once-a-week for 24 weeks
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Eldecalcitol (ELD)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Alendronate (ALN)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Both ELD and ALN
Number of subjects: 124
Study: 36064325

Group type: EXPERIMENTAL
Intervention: NER1006 (1 L polyethylene glycol-based preparation)
Number of subjects: 214
Study: 33788465

Group type: EXPERIMENTAL
Intervention: Wei's triple nine needling combined with conventional medication
Number of subjects: 90

Group type: COMPARATOR
Intervention: Conventional medication
Number of subjects: 90
Study: 36429402

Group type: EXPERIMENTAL
Intervention: ad hoc mobile app and health data measuring devices
Number of subjects: 70
Study: 33222703

Group type: EXPERIMENTAL
Intervention: Mediterranean diet (MD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Inactive control therapy (befriending)
Number of subjects: 0
Study: 35361653

Group type: EXPERIMENTAL
Intervention: Combined exercise (aerobic and resistance) + cognitive training (NEUROPEAK)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined exercise + control cognitive training (web searching)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Control exercise (balance and toning) + cognitive training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Control exercise + control cognitive training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adherence to the interventions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pre-allocation preference for a given intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Individual and combined interventions
Number of subjects: 0
Study: 34144176

Group type: EXPERIMENTAL
Intervention: Single-dose HPV vaccination
Number of subjects: 0

Group type: COMPARATOR
Intervention: Two-dose HPV vaccination
Number of subjects: 0
Study: 32792427

Group type: EXPERIMENTAL
Intervention: Microwave ablation (MWA)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Radiofrequency ablation
Number of subjects: 60
Study: 33942397

Group type: EXPERIMENTAL
Intervention: Sugarcane bagasse treated with Lactobacillus casei TH14, cellulase and molasses (BG)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Rice straw (RS)
Number of subjects: 8
Study: 33305643

Group type: EXPERIMENTAL
Intervention: Circular electrodes
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Rectangular electrodes
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Right DLPFC tDCS
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Active tDCS
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 24
Study: 35267477

Group type: EXPERIMENTAL
Intervention: Ramucirumab monotherapy at 8 mg/kg Q2W
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: Ramucirumab monotherapy at 12 mg/kg Q2W
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: Ramucirumab monotherapy at 6 mg/kg QW
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: Paclitaxel (80 mg/m2-D1D8D15) plus ramucirumab (12 mg/kg-Q2W)
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: Paclitaxel (80 mg/m2-D1D8D15) plus ramucirumab (8 mg/kg-Q2W)
Number of subjects: 409

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 409
Study: 32488687

Group type: EXPERIMENTAL
Intervention: Family Check‐Up 4 Health (FCU4Health)
Number of subjects: 141
Study: 32037592

Group type: EXPERIMENTAL
Intervention: Physiology-guided incremental optimization strategy
Number of subjects: 260

Group type: COMPARATOR
Intervention: Blinded post-PCI coronary physiology measurements
Number of subjects: 260
Study: 36217451

Group type: EXPERIMENTAL
Intervention: Transperineal (TP) imaging-targeted biopsies
Number of subjects: 0

Group type: COMPARATOR
Intervention: Transrectal (TR) imaging-targeted biopsies
Number of subjects: 0
Study: 32200381

Group type: EXPERIMENTAL
Intervention: Community weight loss programme
Number of subjects: 73

Group type: COMPARATOR
Intervention: Usual weight loss advice from a practice nurse
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Whole cohort
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: 5% weight loss
Number of subjects: 73
Study: 33853868

Group type: EXPERIMENTAL
Intervention: Virtual learning collaboratives
Number of subjects: 45

Group type: COMPARATOR
Intervention: Matched control group
Number of subjects: 45
Study: 33433318

Group type: EXPERIMENTAL
Intervention: Ferumoxytol 510 mg once or twice quarterly
Number of subjects: 173

Group type: COMPARATOR
Intervention: Sodium ferric gluconate 125 mg weekly
Number of subjects: 173
Study: 36171282

Group type: EXPERIMENTAL
Intervention: Intracorporeal anastomosis (ICA)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Extracorporeal anastomosis (ECA)
Number of subjects: 68
Study: 32151220

Group type: EXPERIMENTAL
Intervention: GIK (200 g/L glucose, 66.7 U/L insulin, and 80 mmol/L KCl) administered intravenously at 1 mL/kg per hour 10 minutes before anesthesia and continuously for 12.5 hours
Number of subjects: 930

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 930
Study: 34177805

Group type: EXPERIMENTAL
Intervention: Yoga-based lifestyle modification protocol (YLP) for 9 consecutive days, followed by daily home and weekly supervised practices for 3 months.
Number of subjects: 3380

Group type: EXPERIMENTAL
Intervention: Yoga-based lifestyle modification protocol (YLP)
Number of subjects: 3380

Group type: COMPARATOR
Intervention: Standard of care advice for diabetes prevention
Number of subjects: 3380
Study: 32568616

Group type: EXPERIMENTAL
Intervention: Dense V-Network algorithm
Number of subjects: 100
Study: 34823258

Group type: EXPERIMENTAL
Intervention: CADe
Number of subjects: 1076

Group type: EXPERIMENTAL
Intervention: CAQ
Number of subjects: 1076

Group type: EXPERIMENTAL
Intervention: CADe plus CAQ (COMBO)
Number of subjects: 1076

Group type: COMPARATOR
Intervention: Control
Number of subjects: 1076
Study: 32990570

Group type: EXPERIMENTAL
Intervention: Mitral valve bioprosthesis
Number of subjects: 355

Group type: COMPARATOR
Intervention: Mechanical prosthesis
Number of subjects: 355
Study: 36127888

Group type: EXPERIMENTAL
Intervention: sFlt‐1 levels in patients with placenta accreta spectrum disorder
Number of subjects: 80

Group type: COMPARATOR
Intervention: sFlt‐1 levels in patients with normal pregnancies (control group)
Number of subjects: 80
Study: 32715401

Group type: EXPERIMENTAL
Intervention: TXA (intravenous tranexamic acid)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control (normal saline)
Number of subjects: 100
Study: 32049887

Group type: EXPERIMENTAL
Intervention: VL20
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: VL40
Number of subjects: 64

Group type: COMPARATOR
Intervention: VL0
Number of subjects: 64

Group type: COMPARATOR
Intervention: VL10
Number of subjects: 64
Study: 35088469

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Standard Care
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: HIIT
Number of subjects: 63
Study: 34344638

Group type: EXPERIMENTAL
Intervention: D‐VMP
Number of subjects: 706

Group type: COMPARATOR
Intervention: VMP
Number of subjects: 706
Study: 35130487

Group type: EXPERIMENTAL
Intervention: Multi-dose priming regimen (days 1, 8, and 29) with 9 × 10^5 PfSPZ/dose
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Multi-dose priming regimens (days 1, 3, 5, 7, and 113; days 1, 3, 5, and 7; days 1, 3, 5, 7, and 29)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control group (normal saline)
Number of subjects: 84
Study: 34157056

Group type: EXPERIMENTAL
Intervention: Social Contact Self‐Efficacy Scale for Third Agers (SET)
Number of subjects: 1139
Study: 35356927

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no adjuvant chemotherapy)
Number of subjects: 0
Study: 33069172

Group type: EXPERIMENTAL
Intervention: Early intensive blood pressure lowering
Number of subjects: 1632

Group type: COMPARATOR
Intervention: Guideline-recommended blood pressure lowering
Number of subjects: 1632
Study: 32600394

Group type: EXPERIMENTAL
Intervention: Real rTMS (1 Hz/1200 pulses/8 trains/90% resting motor threshold) delivered over the right DLPFC for 5 consecutive days/week for 4 weeks
Number of subjects: 90

Group type: COMPARATOR
Intervention: Sham‐rTMS
Number of subjects: 90
Study: 35076087

Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Naltrexone (2 pills)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Naltrexone (1 pill)
Number of subjects: 0
Study: 33386756

Group type: EXPERIMENTAL
Intervention: 10 mg THC
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 30 mg THC
Number of subjects: 30

Group type: COMPARATOR
Intervention: THC blood concentration
Number of subjects: 30
Study: 35568049

Group type: EXPERIMENTAL
Intervention: WEVEE VLP vaccine (6 μg, 30 μg, or 60 μg) with or without aluminium hydroxide suspension (alum) adjuvant, administered by intramuscular injection at study day 0 and week 8.
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 30 μg plus alum group
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: All doses of WEVEE VLP vaccine
Number of subjects: 30
Study: 34301652

Group type: EXPERIMENTAL
Intervention: FCal-POCT (point-of-care testing for faecal calprotectin) after online training
Number of subjects: 406

Group type: COMPARATOR
Intervention: Dutch GP guidelines (control group)
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: FCal-POCT
Number of subjects: 406
Study: 32700421

Group type: EXPERIMENTAL
Intervention: Ertugliflozin 5 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ertugliflozin 15 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-ertugliflozin
Number of subjects: 0
Study: 34839481

Group type: EXPERIMENTAL
Intervention: Intravenous iron (1,000 mg dose of low-molecular weight iron dextran over one hour)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Intravenous iron
Number of subjects: 23

Group type: COMPARATOR
Intervention: Oral iron
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Both groups (IV iron and oral iron)
Number of subjects: 23
Study: 33563257

Group type: EXPERIMENTAL
Intervention: Levonorgestrel releasing intrauterine system (LNG-IUS)
Number of subjects: 201
Study: 33542371

Group type: EXPERIMENTAL
Intervention: Cionni modified capsular tension rings (MCTR) during lens subluxation surgery
Number of subjects: 66
Study: 32421159

Group type: EXPERIMENTAL
Intervention: Endovascular treatment (EVT) with standard medical care
Number of subjects: 67

Group type: COMPARATOR
Intervention: Standard medical care only (control group)
Number of subjects: 67
Study: 35149625

Group type: EXPERIMENTAL
Intervention: Progressive muscle relaxation
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Benson relaxation technique
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study: 33292982

Group type: EXPERIMENTAL
Intervention: Hot conditions (42.3 ± 0.3 °C; 28.4 ± 5.2% Rh)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Cool conditions (24.0 ± 0.0 °C; 14.4 ± 3.4% Rh)
Number of subjects: 22
Study: 36079884

Group type: EXPERIMENTAL
Intervention: 6AA (12 g of non‐essential amino acid formulation orally, 4 g three times a day)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (equivalent doses to 6AA)
Number of subjects: 50
Study: 33452595

Group type: EXPERIMENTAL
Intervention: Exenatide (twice daily for 16 weeks)
Number of subjects: 190
Study: 32145287

Group type: EXPERIMENTAL
Intervention: Biodegradable stents (slow, medium, fast degradation)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Biodegradable stents
Number of subjects: 38
Study: 34000894

Group type: EXPERIMENTAL
Intervention: 30-minute use of smartphone social network apps
Number of subjects: 16

Group type: COMPARATOR
Intervention: Watching a documentary
Number of subjects: 16
Study: 32217045

Group type: EXPERIMENTAL
Intervention: Pulse Pressure Variation (PPV)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Area under the receiver operating characteristic curve for icIVC
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Area under the receiver operating characteristic curve for idIVC
Number of subjects: 22
Study: 33994179

Group type: COMPARATOR
Intervention: Custom-made foot orthosis
Number of subjects: 27

Group type: COMPARATOR
Intervention: Prefabricated foot orthosis
Number of subjects: 27
Study: 33126825

Group type: EXPERIMENTAL
Intervention: PrEP
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 34922061

Group type: EXPERIMENTAL
Intervention: Anthocyanins (320 mg daily for 12 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 34127089

Group type: EXPERIMENTAL
Intervention: Lurasidone monotherapy 20-60 mg/d
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Lurasidone monotherapy 80-120 mg/d
Number of subjects: 161

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Lurasidone adjunctive therapy 20-120 mg/d + Li/VPA
Number of subjects: 161

Group type: COMPARATOR
Intervention: Placebo + Li/VPA
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Lurasidone monotherapy
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Lurasidone adjunctive therapy
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Lurasidone monotherapy (long-term)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Adjunctive lurasidone therapy (long-term)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Lurasidone monotherapy (pediatric)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Placebo (pediatric)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Lurasidone (pediatric)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Lurasidone (pediatric long-term)
Number of subjects: 161
Study: 35847029

Group type: EXPERIMENTAL
Intervention: Jinzhen Oral Liquid (JZOL) and Ambroxol Hydrochloride and Clenbuterol Hydrochloride Oral Solution (AHCHOS) placebo
Number of subjects: 1000

Group type: COMPARATOR
Intervention: AHCHOS and JZOL placebo
Number of subjects: 1000
Study: 32963028

Group type: EXPERIMENTAL
Intervention: Corticosteroid therapy (dexamethasone)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 36469833

Group type: EXPERIMENTAL
Intervention: R-DHAP (rituximab plus dexamethasone, high-dose cytarabine, and cisplatin)
Number of subjects: 0

Group type: COMPARATOR
Intervention: R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: R-DHAP
Number of subjects: 0

Group type: COMPARATOR
Intervention: R-CHOP
Number of subjects: 0
Study: 33481813

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (15 mg daily)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 80
Study: 32718308

Group type: EXPERIMENTAL
Intervention: Pharmacotherapy for reduction in drinking
Number of subjects: 20
Study: 34524652

Group type: EXPERIMENTAL
Intervention: Greater than one’s usual negative affect and shape/weight-related cognitions
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Spending time on social media
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Attending social events
Number of subjects: 25
Study: 33931884

Group type: EXPERIMENTAL
Intervention: Losmapimod 15 mg (Part B)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Losmapimod 7.5 mg (Part B)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Losmapimod 15 mg (Part C)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (Part B)
Number of subjects: 20
Study: 32381158

Group type: EXPERIMENTAL
Intervention: Evolocumab
Number of subjects: 22655

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22655

Group type: EXPERIMENTAL
Intervention: Achieved LDL-C <20 mg/dl
Number of subjects: 22655

Group type: EXPERIMENTAL
Intervention: Achieved LDL-C ≥100 mg/dl
Number of subjects: 22655
Study: 35976578

Group type: EXPERIMENTAL
Intervention: NOL-guided fentanyl dosing (NOL)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Standard care (SOC)
Number of subjects: 75
Study: 33881715

Group type: EXPERIMENTAL
Intervention: YYHG high-dose
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: YYHG low-dose
Number of subjects: 288

Group type: COMPARATOR
Intervention: Positive control (XSTG)
Number of subjects: 288

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: YYHG treatment
Number of subjects: 288
Study: 32282021

Group type: EXPERIMENTAL
Intervention: Former smokers
Number of subjects: 484

Group type: EXPERIMENTAL
Intervention: Current smokers
Number of subjects: 484

Group type: EXPERIMENTAL
Intervention: Former smokers (MPO-ANCA-positive disease)
Number of subjects: 484

Group type: EXPERIMENTAL
Intervention: Current smokers (MPO-ANCA-positive disease)
Number of subjects: 484

Group type: EXPERIMENTAL
Intervention: Former smokers (PR3-ANCA-positive AAV)
Number of subjects: 484

Group type: EXPERIMENTAL
Intervention: Current smokers (PR3-ANCA-positive AAV)
Number of subjects: 484
Study: 32207836

Group type: EXPERIMENTAL
Intervention: Oral naloxone co-administration with ticagrelor and morphine
Number of subjects: 0
Study: 35141806

Group type: EXPERIMENTAL
Intervention: L-PRF
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: L-PRF + DPSC
Number of subjects: 13
Study: 32883493

Group type: EXPERIMENTAL
Intervention: Metastasectomy
Number of subjects: 2258

Group type: EXPERIMENTAL
Intervention: Metastasectomy (liver metastasis only)
Number of subjects: 2258
Study: 33270047

Group type: EXPERIMENTAL
Intervention: UV photofunctionalization
Number of subjects: 17

Group type: COMPARATOR
Intervention: Untreated miniscrews (Control)
Number of subjects: 17
Study: 35635850

Group type: EXPERIMENTAL
Intervention: RobotReviewer-assisted RoB assessments
Number of subjects: 145

Group type: COMPARATOR
Intervention: Control group (human effort only)
Number of subjects: 145
Study: 34226985

Group type: EXPERIMENTAL
Intervention: PROERD intervention (10 classes conducted by trained police officers)
Number of subjects: 4030
Study: 32228267

Group type: EXPERIMENTAL
Intervention: Risk score based on age >52, WBC >10 × 10^9/L, PLT ≤10 × 10^9/L, LDH >500 U/L
Number of subjects: 570
Study: 33742307

Group type: EXPERIMENTAL
Intervention: Financial incentive paid at testing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Financial incentive
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nudge
Number of subjects: 0
Study: 32990365

Group type: EXPERIMENTAL
Intervention: Arrowroot kefir flour (24 hr of fermentation; AKF1)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Arrowroot kefir flour (48 hr of fermentation; AKF2)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control flour (CF)
Number of subjects: 6
Study: 34324700

Group type: EXPERIMENTAL
Intervention: Fremanezumab monthly (675 mg at baseline and 225 mg at weeks 4 and 8)
Number of subjects: 571

Group type: EXPERIMENTAL
Intervention: Fremanezumab quarterly (675 mg at baseline and placebo at weeks 4 and 8)
Number of subjects: 571

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 571

Group type: EXPERIMENTAL
Intervention: Fremanezumab monthly
Number of subjects: 571

Group type: EXPERIMENTAL
Intervention: Fremanezumab quarterly
Number of subjects: 571
Study: 33201236

Group type: EXPERIMENTAL
Intervention: Fall-prevention tool kit
Number of subjects: 37231
Study: 34083627

Group type: EXPERIMENTAL
Intervention: 3-month dual antiplatelet therapy (DAPT)
Number of subjects: 2083

Group type: EXPERIMENTAL
Intervention: 12-month dual antiplatelet therapy (DAPT)
Number of subjects: 2083
Study: 33022991

Group type: EXPERIMENTAL
Intervention: Almond-based Low Carbohydrate Diet (a‐LCD)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Low-Fat Diet (LFD)
Number of subjects: 45
Study: 35418427

Group type: EXPERIMENTAL
Intervention: Azithromycin (10 mg/kg/day) for 3 days
Number of subjects: 570

Group type: EXPERIMENTAL
Intervention: High-dose vitamin D (2000 IU/day + standard dose 400 IU/day) for 1 year
Number of subjects: 570
Study: 34808749

Group type: EXPERIMENTAL
Intervention: Radial shock wave therapy (RSWT) in the lateral elbow area plus scapular back area
Number of subjects: 54

Group type: COMPARATOR
Intervention: Radial shock wave therapy (RSWT) only in the lateral elbow area
Number of subjects: 54
Study: 32093769

Group type: EXPERIMENTAL
Intervention: JOURNEY II Bi-Cruciate Stabilised knee arthroplasty
Number of subjects: 80

Group type: COMPARATOR
Intervention: GENESIS II total knee arthroplasty
Number of subjects: 80
Study: 35172198

Group type: EXPERIMENTAL
Intervention: Canagliflozin 100mg daily
Number of subjects: 4401

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4401
Study: 34346563

Group type: EXPERIMENTAL
Intervention: 9-gene signature
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 9-gene signature combined with TNM stage and age
Number of subjects: 0
Study: 32275362

Group type: EXPERIMENTAL
Intervention: Herb-partitioned moxibustion at fanwei point, 40 min each time, once a day for 5 times a week for 6 weeks
Number of subjects: 134

Group type: COMPARATOR
Intervention: Itopride hydrochloride tablets, 50 mg each time, three times a day for 6 weeks
Number of subjects: 134
Study: 34496174

Group type: COMPARATOR
Intervention: Iron syrup
Number of subjects: 3300

Group type: COMPARATOR
Intervention: Multiple micronutrient powders
Number of subjects: 3300

Group type: COMPARATOR
Intervention: Iron syrup and multiple micronutrient powders
Number of subjects: 3300

Group type: COMPARATOR
Intervention: Iron syrup, multiple micronutrient powders, and placebo
Number of subjects: 3300